Synapse - Glenn Heller

Search Within

Glenn Heller

Results (400)

Lorlatinib tolerability and association with clinical outcomes in patients with advanced ALK- or ROS1-rearranged NSCLC: A brief report

Journal Article

Thummalapalli, R.; Choudhury, N. J.; Ehrich, F.; Beardslee, T.; Brazel, D.; Zhang, S. S.; Merchant, S.; Chen, M. F.; Heller, G.; Ramalingam, S. S.; more...
JTO Clinical and Research Reports (2023)

Fulltext@MSK | Save

Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)

Meeting Abstract

Aggarwal, R. R.; Dooley, K.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies

Meeting Abstract

Jensen, J. L.; Bobek, O.; Chan, I. C. C.; Hillman, D. W.; Heller, G.; Druley, T. E.; Morris, M. J.; Milowsky, M. I.; Beltran, H.; Bolton, K. L.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Randomized phase III study of enzalutamide compared with enzalutamide plus abiraterone for metastatic castration-resistant prostate cancer (Alliance A031201 trial)

Journal Article

Morris, M. J.; Heller, G.; Hillman, D. W.; Bobek, O.; Ryan, C.; Antonarakis, E. S.; Bryce, A. H.; Hahn, O.; Beltran, H.; Armstrong, A. J.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers

Journal Article

Choudhury, N. J.; Marra, A.; Sui, J. S. Y.; Flynn, J.; Yang, S. R.; Falcon, C. J.; Selenica, P.; Schoenfeld, A. J.; Rekhtman, N.; Gomez, D.; more...
Journal of Thoracic Oncology (2023)

Fulltext@MSK | Save

A modified net reclassification improvement statistic

Journal Article

Heller, G.
Journal of Statistical Planning and Inference (2023)

Fulltext@MSK | Save

Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rao, A.; Heller, G.; Ryan, C. J.; VanderWeele, D. J.; Lewis, L. D.; Tan, A.; Watt, C.; Chen, R. C.; Kohli, M.; Barata, P. C.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19)

Meeting Abstract

Aggarwal, R. R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T. B.; Appleman, L. J.; Weckstein, D. J.; Patnaik, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

The ectonucleotidase CD39 identifies tumor-reactive CD8(+) T cells predictive of immune checkpoint blockade efficacy in human lung cancer

Journal Article

Chow, A.; Uddin, F. Z.; Liu, M.; Dobrin, A.; Nabet, B. Y.; Mangarin, L.; Lavin, Y.; Rizvi, H.; Tischfield, S. E.; Quintanal-Villalonga, A.; more...
Immunity (2023)

Fulltext@MSK | Save

PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)

Meeting Abstract

Aggarwal, R.; Heller, G.; Hillman, D.; Xiao, H.; Picus, J.; Wang, J.; Taplin, M. E.; Dorff, T.; Appleman, L. J.; Weckstein, D.; more...
Annals of Oncology (2022)

Fulltext@MSK | Save